



TITLE: The Use of OxyNEO® and OxyContin® in Adults: A Review of the Evidence on Safety

DATE: 20 September 2011

CONTEXT AND POLICY ISSUES:

One in three Canadians experience chronic pain in their lifetime and opioid analgesics are the most commonly prescribed treatment.^{1,2} Opioid prescriptions have increased as chronic pain has been recognized as a treatable condition and prescribers have become familiar with opioid analgesics.³ OxyContin® (Purdue Pharma, www.purdue.ca) is indicated for the management of moderate to severe pain when continuous analgesic is needed for an extended period of time.⁴ OxyContin® contains oxycodone, an opioid agonist with abuse liability similar to that of morphine.⁴ While extended release (ER) formulations were designed to reduce abuse liability, simply chewing or crushing oxycodone extended release (OER) tablets and either inhaling, injecting or swallowing them, rapidly releases oxycodone producing a heroin-like euphoria with potentially lethal consequences.⁴⁻⁹ OxyContin® is often consumed with alcohol, other opioids, illicit drugs or other central nervous system depressants despite box warnings.^{4,10,11} In 2002, a risk management program, Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®), was implemented to capture and analyze the prevalence of abuse and diversion of OER by United States 3-digit ZIP code.^{12,13}

A tamper-resistant formulation of OxyContin®, known as OxyNEO® (Purdue Pharma, Stamford, CT, USA), has recently been developed in an effort to prevent individuals seeking OxyContin®'s euphoric properties from unintended overdose.¹ OxyNEO® was marketed in the United States in April 2010^{14,15} as a difficult to crush tablet that when hydrated, forms a viscous gel that resists oxycodone extraction for injection purposes.¹⁶ Having received a notice of compliance from Health Canada in August 2011,¹⁷ OxyNEO® will be replacing OxyContin® on the Canadian market prompting questions regarding its ability to deter abuse, how to integrate the new formulation into clinical practice, and how to identify candidates for therapy.¹⁸

The purpose of this report is to review the clinical evidence on the safety and harms of OxyNEO® and OxyContin® in adults with moderate to severe chronic pain.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material. It may be copied and used for non-commercial purposes, provided that attribution is given to CADTH.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners' own terms and conditions.

RESEARCH QUESTIONS:

1. What is the clinical evidence on the safety and harms of OxyNEO® in adults?
2. What is the clinical evidence on the safety and harms of OxyContin® in adults?

KEY MESSAGE:

No evidence was found regarding the safety and harms of OxyNEO® in adults. Oxycodone prescriptions and oxycodone-related deaths increased after OxyContin® ER was added to a provincial drug formulary. While most deaths were accidental polydrug overdoses and deliberate overdoses were more common in older pain patients and women.

METHODS:

Literature search strategy

A limited literature search was conducted on key resources including Medline, EMBASE, PubMed, The Cochrane Library (2010, Issue 8), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied to limit retrieval by publication type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2006 and August 26, 2011.

Selection Criteria and Methods

One reviewer screened citations to identify health technology assessments, systematic reviews, meta-analyses, randomized and non-randomized studies regarding the safety and harms of OxyNEO® and OxyContin® in adults. Potentially relevant articles were ordered based on titles and abstracts, where available. Full-text articles were considered for inclusion according to the selection criteria listed in Table 1.

Table 1: Selection Criteria

Population	Adults on pain medications
Intervention	<ol style="list-style-type: none"> 1. Reformulation of oxycodone, new oxycodone formulation and OxyNEO® 2. Extended release Oxycodone, old oxycodone formulation and OxyContin®
Comparator	Not applicable
Outcomes	Safety Clinical harms Patient adverse events
Study Designs	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials (RCTs), non-randomized studies

Exclusion Criteria

Articles were excluded if they did not satisfy the selection criteria, provided incomplete study methods, or they were narrative reviews or editorials.

Critical Appraisal of Individual Studies

Non-randomized studies were assessed for quality using the Down's and Black instrument.¹⁹ Instead of calculating numeric scores, the strengths and limitations of each study were described.

SUMMARY OF EVIDENCE:

Quantity of Research Available

The literature search yielded 214 citations. Upon screening titles and abstracts, eight potentially relevant articles were retrieved for full-text review. No additional potentially relevant reports were retrieved from grey literature or hand searching. Of the eight potentially relevant reports, one did not contain the intervention of interest, one was an editorial, and two were narrative reviews. No articles were identified regarding the safety and patient adverse events of OxyNEO® in adults with moderate to severe pain. Three articles reported on the safety of OxyContin® in adults^{2,3,20} and one article reported on patient adverse events related to OxyContin® treatment.²¹ The process of study selection is outlined in the PRISMA flowchart (Appendix 1). Additional articles of potential interest are provided in Appendix 2.

Summary of Study Characteristics

Study design

Two retrospective database case series,^{2,20} one retrospective observational database cohort,³ and a post-market surveillance study involving two clinical trials²¹ were selected for review. The articles originated from Australia,²⁰ Canada,² the United States³ and China²¹ and ranged in date from 2007^{3,21} to 2011.²⁰

Population

An Australian retrospective database case series reported on 70 cases autopsied at the Department of Forensic Medicine, New South Wales, between 1999 and 2008 in which the cause of death was oxycodone toxicity.²⁰ A Canadian retrospective database case series reported on 234 opioid-related deaths recorded in the Office of the Chief Coroner of Ontario between 1991 and 2004.² The retrospective observational database cohort reported adverse events in 5,684 Oregon fee-for service Medicaid recipients newly prescribed ER opioids between 2000 and 2004.³ The two-study, multicentre open-label post-market surveillance study reported the clinical efficacy and safety of OER in 386 moderate to severe non-cancer pain patients.²¹

Interventions

In New South Wales, all unnatural deaths are reported to the coroner and fatal oxycodone toxicity cases were identified based on standard autopsy.²⁰ While twelve of 70 cases involved oxycodone toxicity and 58 cases involved multiple drug toxicity, oxycodone was not prescribed to the decedent in 30% of cases.²⁰ The Ontario database study analyzed trends in prescribing patterns between 1991 and 2007 and reviewed all opioid-related deaths between 1991 and

2004 following the introduction of oxycodone extended release (OER).² Four-hundred of 464 oxycodone-related deaths involved at least one non-opioid central nervous system depressant; most commonly benzodiazepines, alcohol and cyclic antidepressants.² The Oregon Medicaid retrospective study examined claims for ER opioids including methadone, OER, morphine extended release (MER), and transdermal fentanyl.³ The post-marketing surveillance evaluated the efficacy and safety of OER, 5 mg, 10 mg, 20 mg and 40 mg dosages, for relieving non-cancer pain.²¹

Outcomes

The Australian retrospective database cohort evaluated the demographic characteristics, toxicity and autopsy findings of oxycodone toxicity cases presented to the New South Wales Department of Forensic Medicine between 1999 and 2008.²⁰ The Ontario retrospective database case series evaluated trends in opioid prescribing patterns and opioid-related mortality following the addition of OER to the Ontario drug formulary in 2000.² The United States study evaluated the risk of opioid-related adverse events (AEs) among Oregon fee-for-service Medicaid recipients prescribed ER opioids, including emergency department (ED) visits, hospitalizations, and deaths.³ The study characteristics are summarized in Appendix 3.

Summary of Critical Appraisal

The three retrospective database studies had clearly described research questions, inclusion criteria, patient characteristics, outcome measures and findings.^{2,3,20} However, retrospective studies may suffer from bias as subjects were not randomized to treatment and assessors were not blinded. In a third of cases in the Australian study, oxycodone was not prescribed to the decedent and 25% of cases were known injecting drug users (IDUs), so the population may not be representative of the population prescribed oxycodone for moderate to severe pain.²⁰ While oxycodone tablets were the intervention of interest the time from prescription to death and the dosage were not provided in this study.²⁰ The reviewers for the Ontario retrospective database study pilot tested the data-collection forms to ensure agreement on major data fields, including opioid-related death; however, some deaths may not have been captured as coroners do not investigate all deaths and details were not available after 2004.² In the Oregon retrospective cohort study, claims from administrative databases may lead to misclassification errors as the accuracy of diagnostic codes was not validated.³ As with most retrospective database studies, there may be immortal time bias as dispensed prescriptions may not have been consumed or there may be a time lag between prescription filling and consumption.³ Emergency department visits and hospitalization are nonvalidated surrogates for potential AEs.³

The post-marketing surveillance study had a clearly described research question, inclusion and exclusion criteria, intervention, outcomes, and findings.²¹ This was an open label prospective study where subjects were not randomized to treatment and assessors were not blinded.²¹ The critical appraisal is summarized in Appendix 4.

Summary of Findings

No evidence was identified regarding the safety and harms of OxyNEO® for moderate to severe pain in adults.

Three retrospective database studies^{2,3,20} and a post-marketing surveillance study²¹ provided evidence on the safety, harms and patient AEs associated with OxyContin® in adults with moderate to severe pain (Table 2).

An Australian retrospective database case series of 70 oxycodone-related deaths reported that 58% of cases were men aged 49 years, 21.4% were suicides and oxycodone had not been prescribed to 30% of decedents.²⁰ Twenty-seven percent of cases occurred in IDU and 21% had injected oxycodone tablets prior to death.²⁰ Women were significantly older than men ($t_{68}=4.3$, $p<0.001$), more likely to be married [odds ratio (OR): 3.36, 95% confidence interval (CI) 1.16 to 9.71] and less likely to be an IDU (OR: 0.10, 95% CI 0.03 to 0.50) or to have injected oxycodone prior to death (OR: 0.16, 95% CI 0.03 to 0.76). Cases of suicide were more likely to be older women (OR: 3.78, 95% CI 1.13 to 12.66). Thirty-two percent of non-IDU cases were suicides compared with 6.7% of IDU ($p=0.007$). Of the 14 non-IDU suicides, 12 were chronic pain patients. The mean blood oxycodone concentration in decedents was 9.40 mg/L (range 0.06 mg/L to 53.00 mg/L).²⁰ Other psychoactive substances were detected in all cases; most commonly hypnotosedatives (68%), other opioids (54%), antidepressants (41%), and alcohol (32%).²⁰ Cardiovascular, pulmonary, hepatic, and renal disease was reported in 64%, 49%, 67% and 44% of cases, respectively.²⁰

An Ontario-based database study used time-series analyses to evaluate opioid-related mortality after the introduction of OER.² The number of oxycodone prescriptions increased from 23 per 1,000 to 197 per 1,000 between 1991 and 2007.² Twenty-eight percent of the oxycodone prescriptions dispensed in 2006 were for the OER.² Between 2001 and 2007, the average amount of OER dispensed per prescription increased from 1830 mg to 2280 mg. Similarly, between 1999 and 2004, the annual number of oxycodone-related deaths increased by 416% ($p<0.01$) from 1.39 per million to 7.17 per million.² Oxycodone was present post-mortem in 50 of 75 (67%) patients who were dispensed oxycodone after their last physician visit.² Benzodiazepines, alcohol and cyclic antidepressants were reported in 60%, 44%, and 26% of oxycodone-related deaths, respectively.²

The risk of serious AEs among Medicaid recipients recently prescribed ER opioids was evaluated using a retrospective observational cohort.³ Patients prescribed OER were 35% less likely [adjusted hazard ratio (AHR): 0.45; 95% CI 0.26 to 0.77] to experience an emergency department (ED) visit or hospitalization due to opioid-related AE, 23% lower risk of hospitalization (AHR: 0.77; 95% CI 0.66 to 0.91), 41% lower risk of constipation (AHR: 0.59; 95% CI 0.35 to 1.00), and a 29% lower risk of death (AHR: 0.71; 95% CI 0.54 to 0.94) compared with morphine extended release (MER) recipients.³

A post-marketing surveillance study evaluated the efficacy and safety of OER tablets for relieving moderate to severe non-cancer pain. While constipation was the most common patient AE reported during the first week of treatment this decreased with use.²¹ The study findings are summarized in Appendix 5.

Table 2. Summary of the Clinical Evidence on the Safety, Harms and AE of OxyContin®

Intervention	Evidence	Results
Oxycodone	Retrospective database case series ²⁰	<ul style="list-style-type: none"> Oxycodone was not prescribed to the decedent in 84% of IDU and 32% of other oxycodone-related deaths. Suicides were more likely to occur in older women who were not IDU. Oxycodone-related deaths were often associated with use of hypnotosedatives, other opioids, antidepressants and alcohol and were more common in individuals with pre-existing disease.
OER	Retrospective database case series ²	<ul style="list-style-type: none"> Oxycodone prescriptions increased from 23/100 to 197/1000 between 1991 and 2007. Average OER prescribed increased from 1830 mg to 2280 mg between 2001 and 2007. Oxycodone related deaths increased from 1.39 to 7.17 per million annually between 1991 and 1994. Benzodiazepines, alcohol and cyclic antidepressants were commonly associated with use.
OER	Retrospective observational database cohort ³	<ul style="list-style-type: none"> Patients prescribed OER were less likely to experience an ED visit or hospitalization for an opioid-related AE, or constipation compared to patients who were prescribed MER.
OER	Post-marketing surveillance study ²¹	<ul style="list-style-type: none"> OxyContin® -related constipation decreases with use.

AE: adverse event; ED: emergency department; IDU: injecting drug users; MER: morphine extended release; OER: oxycodone extended release

Limitations

No evidence was identified regarding the safety and harms of OxyNEO® in adults with moderate to severe chronic pain. The quantity of evidence on the safety, harms and patient adverse events related to using OxyContin® in adults with chronic pain is limited to three retrospective database studies and a post-marketing surveillance study.^{2,3,20,21} For instance, patients in retrospective database studies are not randomized to treatment, and assessors are not blinded. Database studies also suffer from misclassification errors when the accuracy of diagnostic codes are not validated, and immortal time bias as drugs may not be consumed as soon as they are dispensed.^{2,3,20} Only the post-marketing surveillance study reported the formulation and dosages of oxycodone studied and hospitalization and ED visits are nonspecific surrogates for potential AEs.

CONCLUSIONS AND IMPLICATIONS FOR DECISION OR POLICY MAKING:

Oxycodone prescriptions and oxycodone-related deaths have increased since 1991 following the addition of OER to the Ontario drug formulary.² Most patients who received a prescription for oxycodone at their last physician visit had oxycodone in their system post-mortem. Benzodiazepines, alcohol and cyclic antidepressants were commonly associated with oxycodone-related deaths. While most deaths were accidental, polydrug overdoses and deliberate overdoses were more likely among older pain patients and women. OER offered a modest safety advantage over MER. OER users experienced a significantly lower risk of ED visits or hospitalization for opioid-related AE, all-cause death, hospitalization, and constipation compared to MER users. Constipation was the most common adverse drug reaction but the incidence decreased with use.

People take more of a drug to experience the euphoria of an opioid whether it is tamper-resistant or not. For this reasons, the benefits of tamper-resistant products need to be determined in large, randomized controlled trials or epidemiological studies designed to track abuse over time in a wide range of relevant populations. A risk management program based on the OxyContin® experience could be prepared to universally capture and analyze the prevalence of abuse and diversion of OxyNEO® as it replaces OxyContin® on the Canadian market.

PREPARED BY:

Canadian Agency for Drugs and Technologies in Health

Tel: 1-866-898-8439


www.cadth.ca

REFERENCES:

1. Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? *CNS Drugs*. 2010 Oct 1;24(10):805-10.
2. Dhalla IA, Mamdani MM, Sivilotti MLA, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. *CMAJ* [Internet]. 2009 Dec 8 [cited 2011 Sep 1];181(12):891-6. Available from: <http://www.cmaj.ca/content/181/12/891.full.pdf+html>
3. Hartung DM, Middleton L, Haxby DG, Koder M, Ketchum KL, Chou R. Rates of adverse events of long-acting opioids in a state Medicaid program. *Ann Pharmacother*. 2007 Jun;41(6):921-8.
4. OxyContin: full prescribing information [Internet]. Pickering (ON): Purdue Pharma; 2010 Nov. [cited 2011 Sep 16]. Available from: <http://www.purduepharma.com/pressroom/news/OxycontinPI.pdf>
5. Fact sheet - misuse and abuse of oxycodone-based prescription drugs [Internet]. Ottawa: Health Canada; 2010 Jan 11. [cited 2011 Sep 16]. Available from: <http://www.hc-sc.gc.ca/hc-ps/pubs/precur/oxycodone/fs-fi/index-eng.php>
6. Paperny AM. Ontario slow to act on prescription drug reforms, doctors charge [Internet]. Toronto: Globe and Mail; 2011 Jul 12. [cited 2011 Sep 15]. Available from: <http://www.theglobeandmail.com/life/health/new-health/health-news/ontario-slow-to-act-on-prescription-drug-reforms-doctors-charge/article2095340/>
7. Study finds huge rise in oxycodone deaths [Internet]. Scarborough (ON): CTV; 2009 Dec 7. [cited 2011 Sep 15]. Available from: http://www.ctv.ca/CTVNews/TopStories/20091207/opioids_091207/
8. Weeks C. High doses of opioids tied to risk of death [Internet]. Toronto: Globe and Mail; 2011 Apr 11. [cited 2011 Sep 16]. Available from: <http://www.theglobeandmail.com/life/health/new-health/conditions/addiction/health-addiction/high-doses-of-opioids-tied-to-risk-of-death/article1980624/>
9. Silversides A. Ontario takes aim at painkiller abuse. *CMAJ* [Internet]. 2009 Oct 13 [cited 2011 Sep 16];181(8):E141-E142. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761466>
10. Weekes J. Oxycontin fact sheet [Internet]. Ottawa: Canadian Centre on Substance Abuse (CCSA); 2006. [cited 2011 Sep 16]. Available from: <http://www.ccsa.ca/2006%20CCSA%20Documents/ccsa-003642-2006.pdf>
11. Fischer B, Rehm J. Deaths related to the use of prescription opioids. *CMAJ* [Internet]. 2009 Dec 8 [cited 2011 Sep 16];181(12):881-2. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789122>

12. McCormick CG, Henningfield JE, Haddox JD, Varughese S, Lindholm A, Rosen S, et al. Case histories in pharmaceutical risk management. *Drug Alcohol Depend.* 2009 Dec 1;105 Suppl 1:S42-S55.
13. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). *Pain Med.* 2007 Mar;8(2):157-70.
14. OxyContin: questions and answers [Internet]. Silver Spring (MD): U.S. Food and Drug Administration (FDA); 2011 May 4. [cited 2011 Sep 15]. Available from: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm207196.htm>
15. FDA approves new formulation for OxyContin [Internet]. Silver Spring (MD): U.S. Food and Drug Administration (FDA); 2010 Apr 5. [cited 2011 Sep 16]. Available from: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm>
16. Burke J. The OxyContin reformulation: is it working? *Pharm Times* [Internet]. 2011 May 16 [cited 2011 Sep 16]. Available from: <http://www.pharmacytimes.com/publications/issue/2011/May2011/DrugDiversion-0511>
17. Notice of compliance information: OxyNEO [Internet]. In: *Drugs and health products*. Ottawa: Health Canada; 2011 May 30 [cited 2011 Sep 26]. Available from: <http://webprod3.hc-sc.gc.ca/noc-ac/index-eng.jsp>.
18. Avoiding abuse, achieving a balance: tackling the opioid public health crisis [Internet]. Toronto: College of Physicians and Surgeons of Ontario; 2010 Sep 8. [cited 2011 Sep 16]. Available from: <http://www.cpso.on.ca/uploadedFiles/policies/positions/Opioid%20report%20final.pdf>
19. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health.* 1998 Jun;52(6):377-84.
20. Darke S, Duflou J, Torok M. Toxicology and characteristics of fatal oxycodone toxicity cases in New South Wales, Australia 1999-2008. *J Forensic Sci.* 2011 May;56(3):690-3.
21. Yuguang H, Bifa F, Wenxue F, Dongping D, Hua X, Shengmei Z, et al. Oxycodone hydrochloride controlled-release tablets (OxyContin): post-marketing surveillance (PMS) study for relieving moderate to severe non-cancer pain. *Eur J Pain Suppl.* 2007 Sep;1(1):41-7.

APPENDIX 1: Selection of Included Studies



APPENDIX 2: Additional Articles of Potential Interest

1. OxyContin: questions and answers [Internet]. Silver Spring (MD): U.S. Food and Drug Administration (FDA); 2011 May 4. [cited 2011 Sep 15]. Available from: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm207196.htm>
2. Fact sheet - misuse and abuse of oxycodone-based prescription drugs [Internet]. Ottawa: Health Canada; 2010 Jan 11. [cited 2011 Sep 16]. Available from: <http://www.hc-sc.gc.ca/hc-ps/pubs/precurs/oxycodone/fs-fi/index-eng.php>
3. FDA approves new formulation for OxyContin [Internet]. Silver Spring (MD): U.S. Food and Drug Administration (FDA); 2010 Apr 5. [cited 2011 Sep 16]. Available from: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm>
4. Study finds huge rise in oxycodone deaths [Internet]. Scarborough (ON): CTV; 2009 Dec 7. [cited 2011 Sep 15]. Available from: http://www.ctv.ca/CTVNews/TopStories/20091207/opioids_091207/
5. Burke J. The OxyContin reformulation: is it working? Pharm Times [Internet]. 2011 May 16 [cited 2011 Sep 16]. Available from: <http://www.pharmacytimes.com/publications/issue/2011/May2011/DrugDiversion-0511>
6. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med. 2007 Mar;8(2):157-70.
7. Fischer B, Rehm J. Deaths related to the use of prescription opioids. CMAJ [Internet]. 2009 Dec 8 [cited 2011 Sep 16];181(12):881-2. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789122>
8. McCormick CG, Henningfield JE, Haddox JD, Varughese S, Lindholm A, Rosen S, et al. Case histories in pharmaceutical risk management. Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S42-S55.
9. Paperny AM. Ontario slow to act on prescription drug reforms, doctors charge [Internet]. Toronto: Globe and Mail; 2011 Jul 12. [cited 2011 Sep 15]. Available from: <http://www.theglobeandmail.com/life/health/new-health/health-news/ontario-slow-to-act-on-prescription-drug-reforms-doctors-charge/article2095340/>
10. Silversides A. Ontario takes aim at painkiller abuse. CMAJ [Internet]. 2009 Oct 13 [cited 2011 Sep 16];181(8):E141-E142. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761466>
11. Weekes J. Oxycontin fact sheet [Internet]. Ottawa: Canadian Centre on Substance Abuse (CCSA); 2006. [cited 2011 Sep 16]. Available from: <http://www.ccsa.ca/2006%20CCSA%20Documents/ccsa-003642-2006.pdf>
12. Weeks C. High doses of opioids tied to risk of death [Internet]. Toronto: Globe and Mail; 2011 Apr 11. [cited 2011 Sep 16]. Available from:

<http://www.theglobeandmail.com/life/health/new-health/conditions/addiction/health-addiction/high-doses-of-opioids-tied-to-risk-of-death/article1980624/>

APPENDIX 3: Summary of Study Characteristics

First Author, Publication Year, Country	Study Design	Patient Characteristics	Intervention	Comparator	Clinical Outcomes Measured
Darke ²⁰ , 2011 Australia	Retrospective database case series	Autopsy cases from DOFM (1999 to 2008) (n=70; 41% M)	Oxycodone	NA	Toxicology, pathology, prescription status, suicide
Dhalla ² , 2009 Canada	Retrospective database case series	Opioid-related deaths from OCCO (1991 to 2004) (n=234; 67% M)	OER	NA	Prescribing, death, healthcare use prior to death
Hartung ³ , 2007 United States	Retrospective observational database cohort	Opioid-related AE from Medicaid (200 to 2004) (n=5684; M: 35)	OER	Methadone, MER, fentanyl	ED visits, hospitalization, death, opioid-related AE
Yuguang ²¹ , 2007 China	2-study multicentre, open-label, prospective, post-market surveillance	Moderate to severe non-cancer pain patients (n ₁ =196; M: 51%; n ₂ =190; M: 52%)	OER (OxyContin® , Mundipharma International, Cambridge, UK) (5mg, 10 mg, 20 mg, 40 mg)	NA	Clinical efficacy and safety

AE: adverse events; DOFM: Department of Forensic Medicine; ED: emergency department; M: male; MER: morphine extended release; NA: not applicable; n₁: number of subjects in study 1; n₂: number of subjects in study 2; OCCO: Office of the Chief Coroner of Ontario; OER: oxycodone extended release

APPENDIX 4: Summary of Critical Appraisal

First Author, Publication Year Country	Strengths	Limitations
Darke ²⁰ 2011 Australia	<ul style="list-style-type: none"> • Research question and inclusion criteria were established before conducting the study. • Main outcome measures and findings, mostly patient characteristics, are clearly described. 	<ul style="list-style-type: none"> • While all unnatural death cases are reported, some suicide cases may be missed if they occur without the presence of notes or statements. • While oxycodone tablets are the intervention, formulation and dosage were not provided. • In a third of cases, oxycodone was not prescribed to the decedent so they may not be representative of the population prescribed oxycodone for moderate to severe chronic pain. • This is a retrospective case series and assessors are not blinded. Time from prescription to death was not reported. • Approximately 25% of cases were known IDU and oxycodone tablets were injected immediately prior to death by a fifth.
Dhalla ² . 2009 Canada	<ul style="list-style-type: none"> • The objective, patient characteristic, main outcomes and findings were clearly described. • Data abstraction forms were pilot tested before data-collection to ensure agreement on major data fields including whether death was opioid-related. 	<ul style="list-style-type: none"> • This is a retrospective case series; patients were not randomized and assessors were not blinded. • Some opioid-related deaths may not have been captured as coroners do not investigate all deaths and detailed opioid-related death data were not available after 2004. • Most deaths involved a single opioid but most opioids-related deaths involved at least one non-opioid central nervous system depressant that could impact outcomes.

First Author, Publication Year Country	• Strengths	• Limitations
Hartung ³ 2007 United States	<ul style="list-style-type: none"> The objective, patient characteristics, interventions, outcomes, and main findings are well described. 	<ul style="list-style-type: none"> This is a retrospective observational database cohort study and assessors are not blinded and patients were not randomized to treatment. Claims from administrative databases may lead to misclassification errors as the accuracy of diagnostic codes was not validated. Outcomes (any ED or hospitalization) were often a nonspecific surrogate for potential AE. Dispensed prescriptions may not have been consumed.
Yuguang ²¹ 2007 China	<ul style="list-style-type: none"> The objective, patient characteristics, interventions, outcomes, and main findings are well described. 	<ul style="list-style-type: none"> This is an open label, prospective, post-market surveillance study; assessors are not blinded and patients were not randomized to treatment.

AE: adverse event; ED: emergency department; IDU: injecting drug users

APPENDIX 5: Summary of Findings

First Author, Publication Year Country	Main Study Findings	Authors' Conclusions
<p>Darke 2011²⁰ Australia</p>	<p>Oxycodone deaths (1999-2008): 70</p> <p>IDU were significantly younger than other cases (36.5 vs. 56.6, $t_{68} < 0.001$)</p> <p>Oxycodone was not prescribed to decedent in 84.3% of IDU and 31.6% of other cases (OR: 11.65, 95% CI 3.42 to 39.72)²⁰</p> <p>Women were older than men ($t_{68} = 4.3$, $p < 0.001$), more likely to be married (OR: 3.36, 95% CI 1.16 to 9.71), and less likely to be an IDU (OR: 0.10, 95% CI 0.03 to 0.50) or to inject oxycodone before death (OR: 0.16, 95% CI 0.03 to 0.76).²⁰</p> <p>Suicides were more likely to be women (OR: 3.78, 95% CI 1.13-12.66), and significantly older (58.7 vs 46.3 years, $t_{68} < 2.7$, $p < 0.01$); 6.7% were IDU ($p = 0.07$), 32.7% were non-IDU. Of the non-IDU suicides, 12 were chronic pain patients.²⁰</p> <p>Mean blood oxycodone: 0.40 mg/L Other psychoactive substances: 68% hypnotosedatives, 54% other opioids, 41% antidepressants, 32% alcohol. Pre-existing disease: 64% CV, 49% pulmonary, 67% hepatic, 43% renal.²⁰</p> <p>IDU were more likely to have hepatic disease (88.9% vs 58.3%, OR: 5.71, 95% CI 1.18 to 27.68) and non-IDU to have CVD (71.4% vs 44.4%, OR: 3.13, 95% CI 1.02 to 9.52).</p>	<p>"While most cases were accidental, polydrug overdoses, and deliberate overdose was prominent among older pain patients and women".²⁰</p>

First Author, Publication Year Country	Main Study Findings	Authors' Conclusions
Dhalla 2009 ² Canada	<p>Oxycodone prescriptions rose from 23/1000 (1991) to 197/1000 (2007). Of 2.3 million oxycodone prescriptions dispensed (2006), 28% were for OER. Average OER prescribed increased 1830 mg (2001) to 2280 mg (2007)</p> <p>Opioid-related deaths increased from 13.7/million (1991) to 27.2/million (1994). Median age: 40 years; M: 67%; 1847 (52%) unintentional, 803 (24%) suicide, 725 (22%) undetermined.</p> <p>Between 1999 and 2004, oxycodone-related deaths increased from 1.39 to 7.17 per million annually. Fifty (66.7%) of 75 individuals who were dispensed oxycodone following their last physician visit had oxycodone present on post-mortem toxicological analysis.²</p> <p>Benzodiazepines (60%), alcohol (44%) and cyclic antidepressants (26%) were commonly related to oxycodone use.²</p>	<p>“Opioid-related deaths in Ontario have increased since 1991 due to the addition of long-acting oxycodone to the provincial drug formulary. Most deaths are unintentional. Frequent visits to a physician and prescriptions for opioids the month before death suggests a missed opportunity for prevention”.²</p>
Hartung 2007 ³ United States	<p>Patients prescribed OER were 35% less likely (AHR: 0.45; 95% CI 0.26 to 0.77) to experience and ED or hospitalization involving an opioid-related AE, 23% lower risk of hospitalization (AHR: 0.77; 95% CI 0.66 to 0.91), 41% lower risk of constipation (AHR: 0.59; 95% CI 0.35 to 1.00), and 29% lower risk of death (AHR: 0.71; 95% CI 0.54 to 0.94) compared to those prescribed MER.</p>	<p>OER has a modest safety advantage over MER. OER users experienced significantly lower risk of combined ED or hospitalization for opioid-related AE, as well as for the individual outcomes all-cause death hospitalization, and constipation compared to MER users.</p>
Yuguang 2007 ²¹ China	<p>Constipation was the most common adverse drug reaction in the first week, which decreased to 10% of patients from the second week of treatment.</p>	<p>OER tablets demonstrate superior efficacy for relieving moderate and severe non-cancer pain, as well as a reduction in concomitant medications, and a good safety profile.</p>

AHR: adjusted hazard ratio; CI: confidence interval; CVD: cardiovascular disease; ED: emergency department; IDU: Injecting drug users; MER: morphine extended release; OER: oxycodone extended release; OR: odds ratio